AstraZeneca has filed a lawsuit against the Food and Drug Administration to block approval of generics for its best-selling cholesterol pill Crestor. The cholesterol-lowering pill is AstraZeneca's best-selling drug, accounting for $5 billion of its $23 billion in product sales.
An expert panel has recommended that the nasal form of the influenza vaccine should not be used for the upcoming flu season due to its lack of effectiveness over the past three years. AstraZeneca, the vaccine's manufacturer, generated more than $200 million in sales of FluMist in fiscal 2015.
Drugmakers are making increased use of consumer coupons, which are designed to thwart the high copays used by pharmacy benefit managers and insurers to channel consumers to less-costly generic drugs.
Balancing innovation with the rising costs of therapies and value-based payment models is top of mind this week at the largest annual gathering of oncologists.
Kevin Donovan was named president and CEO of Laconia, N.H.-based LRGHealthcare, effective mid-June. He takes the helm from former CEO Seth Warren, who stepped down in March.
Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.
Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.
There might be another tool in the battle against high drug costs: state consumer protection laws. A potential lawsuit in Massachusetts against drugmaker Gilead over its costly hepatitis C drugs could, if successful, forge a new path for states working to combat the high costs of certain drugs.
Ann Arbor, Mich.-based Millendo Therapeutics announced Tuesday morning it has raised a venture capital round of $62 million, the largest VC round for a drug development company in Michigan history.
Pharmaceutical giants Pfizer and Allergan are reportedly nearing a blockbuster deal that could be announced as soon as this week.
An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.
Drug giant AstraZeneca was denied approval of a diabetes drug combination treatment by U.S. regulators, citing the need for more clinical information.